MYNX CONTROL VENOUS Vascular Closure Device

Move Foward with MYNX CONTROL™ VENOUS Vascular Closure Device (VCD), achieving the fastest time to hemostasis.

Request Additional Information

Move Forward With MYNX

DESIGNED FOR EASY AND CONFIDENT DEPLOYMENT

MYNX CONTROL VENOUS VCD is designed to pair procedural simplicity with enhanced safety & reliability.

ACHIEVES QUICKEST TIME TO HEMOSTASIS

Save valuable staff time and move your patients to a quick recovery and on average eligible to discharge within 3 hours1-3.

RESORBS 3X FASTER THAN COLLAGEN SEALANTS

Quick and consistent resorption within 30 days, leaving nothing behind to impede future re-access1,4.

Designed For Easy and Confident Deployment

Sealant Protection

- Minimizes sealant expansion inside cannula
- Facilitates smooth deployment

Sheath Catch

- Sized to accommodate 6F-12F sheath ID (Inner Diameter)
(Note: Use only with a standard sheath introducer with up to 12 cm effective length. Incompatible with Cook Check-Flo™ Performer™ Introducer)

Tension Indicator

- Prevents vessel tenting allowing for a more consistent seal
- Provides confirmation of correct deployment position

Two-Button Design

- Ergonomic handle and buttons for a simple and easy deployment

Clinical Highlights

Achieves Quickest Time To Hemostasis (TTH)

The ReliaSeal Study* demonstrates significantly less time to hemostasis (TTH) compared to manual compression, while also showing the least mean TTH in a cross-trial comparison of venous closure methods.

 * https://clinicaltrials.gov/study/NCT05554471

 

Data is based on a cross-trial comparison and not head-to-head clinical trials, the data may not be directly comparable due to differences in study protocols, conditions and patient populations.

Discharge Patients Faster

The ReliaSeal Study* demonstrated statistically and clinically significant time to ambulation (TTA) and time to discharge eligibility (TTDE) compared to patients treated with manual compression.

 * https://clinicaltrials.gov/study/NCT05554471

Proven Results

The ReliaSeal Study* demonstrated 100% procedural and device success, as well as 0% minor or major access site complications.

 * https://clinicaltrials.gov/study/NCT05554471

Resorbs 3X Faster Than Collagen Sealants

 

GRIP TECHNOLOGY™ is made of a hydrophilic, bio-inert polyethylene glycol (PEG)1,4.
 

  • Promotes Natural Vessel Healing
     

  • Helps to minimize access site infections 
     

  • Quick and consistent resorption within 30 days1

Procedural Use

Deploying The Balloon

Achieve temporary hemostasis and position at the venotomy.

Place The Sealant

The Grip Tip securely adheres to the vein and Sealant fills the tissue tract. Expands to 3–4 times its original size on contact with blood and subcutaneous fluids, creating a matrix structure for clot formation.

Remove The Device

Achieve secure, extravascular closure with nothing left behind to impede re-access. 

The Final Result

The sealant dissolves within 30 days leaving nothing behind but a healed vein.

Product Characteristics

Scroll, sort or search for the particular MYNX CONTROL VENOUS Vascular Closure Device's part number of interest.

SKU Product Description Sheath Compatibility (F) Qty/box Where Used/Indication
MX61260 MYNX CONTROL VENOUS Vascular Closure Device 6-12 6 - 12 10 Femoral vein

Resources

  1. 1. Cordis 2024 Data on File.
     
  2. 2. Natale A, Mohanty S, Liu PY, et al. Venous Vascular Closure System Versus Manual Compression Following Multiple Access Electrophysiology Procedures: The AMBULATE Trial. JACC Clin Electrophysiol. 2020;6(1):111-124. doi:10.1016/j.jacep.2019.08.013.
     
  3. 3. Mohammed M, Ramirez R, Steinhaus DA, et al. Comparative outcomes of vascular access closure methods following atrial fibrillation/flutter catheter ablation: insights from VAscular Closure for Cardiac Ablation Registry. J Interv Card Electrophysiol. 2022;64(2):301-310. 
    doi:10.1007/s10840-021-00981-5.
     
  4. 4.  U.S. Food and Drug Administration, Center for Drug Evaluation and Research.  VASCADE Vascular Closure System (VCS) P120016 approval letter, January 31, 2013.  https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120016b.pdf.

IFU

Please refer to the Instructions for Use for complete information, including indications, precautions, warnings, and potential adverse events.

Customer Service and Ordering Information

In the United States, email us your question or order, or call us at 800.327.7714.